{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T09:20:38Z","timestamp":1781601638138,"version":"3.54.5"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2013,5,11]],"date-time":"2013-05-11T00:00:00Z","timestamp":1368230400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clin Rheumatol"],"published-print":{"date-parts":[[2013,9]]},"DOI":"10.1007\/s10067-013-2272-9","type":"journal-article","created":{"date-parts":[[2013,5,10]],"date-time":"2013-05-10T05:28:11Z","timestamp":1368163691000},"page":"1407-1412","source":"Crossref","is-referenced-by-count":25,"title":["Severe Guillain\u2013Barr\u00e9 syndrome in a patient receiving anti-TNF therapy. Consequence or coincidence. A case-based review"],"prefix":"10.1007","volume":"32","author":[{"given":"Bonifacio","family":"Alvarez-Lario","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosa","family":"Prieto-Tejedo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda","family":"Colazo-Burlato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jes\u00fas","family":"Macarr\u00f3n-Vicente","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2013,5,11]]},"reference":[{"issue":"Suppl 1","key":"2272_CR1","doi-asserted-by":"crossref","first-page":"S33","DOI":"10.1007\/s10067-010-1638-5","volume":"30","author":"F Breedveld","year":"2011","unstructured":"Breedveld F (2011) The value of early intervention in RA\u2014a window of oportunity. Clin Rheumatol 30(Suppl 1):S33\u2013S39","journal-title":"Clin Rheumatol"},{"key":"2272_CR2","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1093\/rheumatology\/keq209","volume":"50","author":"KL Hyrich","year":"2011","unstructured":"Hyrich KL, Watson KD, Lunt M, Symmons DP, British Society for Rheumatology Biologics Register (BSRBR) (2011) Changes in disease characteristics and response rates among patients in the United Kingdom starting anti-tumour necrosis factor therapy for rheumatoid arthritis between 2001 and 2008. Rheumatology (Oxford) 50:117\u2013123","journal-title":"Rheumatology (Oxford)"},{"issue":"Suppl 2","key":"2272_CR3","doi-asserted-by":"crossref","first-page":"i2","DOI":"10.1136\/annrheumdis-2011-201036","volume":"71","author":"DE Furst","year":"2012","unstructured":"Furst DE, Keystone EC, Braun J, Breedveld FC, Burmester GR, De Benedetti F et al (2012) Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2011. Ann Rheum Dis 71(Suppl 2):i2\u2013i45","journal-title":"Ann Rheum Dis"},{"key":"2272_CR4","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1002\/mus.20924","volume":"37","author":"JP St\u00fcbgen","year":"2008","unstructured":"St\u00fcbgen JP (2008) Tumor necrosis factor\u2014antagonists and neuropathy. Muscle Nerve 37:281\u2013292","journal-title":"Muscle Nerve"},{"key":"2272_CR5","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1002\/art.21814","volume":"54","author":"IS Shin","year":"2006","unstructured":"Shin IS, Baer AN, Kwon HJ, Papadopoulos EJ, Siegel JN (2006) Guillain-Barr\u00e9 and Miller Fisher syndromes occurring with tumor necrosis factor alpha antagonist therapy. Arthritis Rheum 54:1429\u20131434","journal-title":"Arthritis Rheum"},{"key":"2272_CR6","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1136\/ard.2005.043208","volume":"67","author":"S Silburn","year":"2008","unstructured":"Silburn S, Mclvor E, McEntegart A, Wilson H (2008) Guillain-Barr\u00e9 syndrome in a patient receiving anti-tumour necrosis factor for rheumatoid arthritis: a case report and discussion of literature. Ann Rheum Dis 67:575\u2013576","journal-title":"Ann Rheum Dis"},{"key":"2272_CR7","doi-asserted-by":"crossref","first-page":"3107","DOI":"10.1002\/art.10488","volume":"46","author":"M Cisternas","year":"2002","unstructured":"Cisternas M, Guti\u00e9rrez M, Jacobelli S (2002) Successful rechallenge with anti-tumor necrosis factor alpha for psoriatic arthritis after development of demyelinating nervous system disease during initial treatment: comment on the article by Mohan et al. Arthritis Rheum 46:3107\u20133108","journal-title":"Arthritis Rheum"},{"issue":"Suppl 1","key":"2272_CR8","doi-asserted-by":"crossref","first-page":"S53","DOI":"10.1007\/s10067-009-1154-7","volume":"28","author":"A Bouchra","year":"2009","unstructured":"Bouchra A, Benbouazza K, Hajjaj-Hassouni N (2009) Guillain-Barre in a patient with ankylosing spondylitis secondary to ulcerative colitis on infliximab therapy. Clin Rheumatol 28(Suppl 1):S53\u2013S55","journal-title":"Clin Rheumatol"},{"key":"2272_CR9","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1016\/j.semarthrit.2010.06.004","volume":"40","author":"MC Fern\u00e1ndez-Espartero","year":"2011","unstructured":"Fern\u00e1ndez-Espartero MC, P\u00e9rez-Zafrilla B, Naranjo A, Esteban C, Ortiz AM, G\u00f3mez-Reino JJ et al (2011) Demyelinating disease in patients treated with TNF antagonists in rheumatology: data from BIOBADASER, a pharmacovigilance database, and a systematic review. Sem Arthritis Rheum 40:330\u2013337","journal-title":"Sem Arthritis Rheum"},{"key":"2272_CR10","doi-asserted-by":"crossref","first-page":"2862","DOI":"10.1002\/1529-0131(200112)44:12<2862::AID-ART474>3.0.CO;2-W","volume":"44","author":"N Mohan","year":"2001","unstructured":"Mohan N, Edwards ET, Cupps TR, Oliverio PJ, Sandberg G, Crayton H et al (2001) Demyelination ocurring during anti-tumor necrosis factor alpha therapy for inflammatory arthritides. Arthritis Rheum 44:2862\u20132869","journal-title":"Arthritis Rheum"},{"key":"2272_CR11","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1007\/s10067-008-1017-7","volume":"28","author":"PT Kurmann","year":"2009","unstructured":"Kurmann PT, Van Linthoudt D, So AK (2009) Miller-Fisher syndrome in a patient with rheumatoid arthritis treated with adalimumab. Clin Rheumatol 28:93\u201394","journal-title":"Clin Rheumatol"},{"key":"2272_CR12","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.reuma.2011.01.009","volume":"7","author":"P L\u00f3pez M\u00e9ndez","year":"2011","unstructured":"L\u00f3pez M\u00e9ndez P, Mart\u00edn Santana I, Reyes Y\u00e1nez MP, Ruano Hern\u00e1ndez A, Hern\u00e1ndez Beriain JA, Herv\u00e1s Garc\u00eda M (2011) S\u00edndrome men\u00edngeo y s\u00edndrome de Guillain-Barr\u00e8 en un paciente con artritis reumatoide tratado con adalimumab. Reumatol Clin 7:401\u2013403","journal-title":"Reumatol Clin"},{"key":"2272_CR13","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1016\/j.crohns.2011.06.010","volume":"5","author":"M Cesarini","year":"2011","unstructured":"Cesarini M, Angelucci E, Foglietta T, Vernia P (2011) Guillain-Barr\u00e8 syndrome after treatment with human anti-tumor necrosis factor \u03b1 (adalimumab) in a Crohn\u2019s disease patient: case report and literature review. J Crohns Colitis 5:619\u2013622","journal-title":"J Crohns Colitis"},{"key":"2272_CR14","first-page":"592","volume":"30","author":"S Manganelli","year":"2012","unstructured":"Manganelli S, Rossi M, Tuccori M, Galeazzi M (2012) Guillain-Barr\u00e9 syndrome following adalimumab treatment. Clin Exp Rheumatol 30:592","journal-title":"Clin Exp Rheumatol"},{"key":"2272_CR15","first-page":"565","volume":"50","author":"E Soto-Cabrera","year":"2012","unstructured":"Soto-Cabrera E, Hern\u00e1ndez-Mart\u00ednez A, Y\u00e1\u00f1ez H, Carrera R (2012) S\u00edndrome de Guillain-Barr\u00e9. Asociaci\u00f3n con antagonista de FNT\u03b1. Rev Med Inst Mex Seguro Soc 50:565\u2013567","journal-title":"Rev Med Inst Mex Seguro Soc"},{"key":"2272_CR16","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1016\/j.jocn.2008.08.033","volume":"16","author":"S Vucic","year":"2009","unstructured":"Vucic S, Kiernan MC, Cornblath DR (2009) Guillain-Barr\u00e9 syndrome: an update. J Clin Neurosci 16:733\u2013741","journal-title":"J Clin Neurosci"},{"key":"2272_CR17","doi-asserted-by":"crossref","first-page":"2294","DOI":"10.1056\/NEJMra1114525","volume":"366","author":"N Yuki","year":"2012","unstructured":"Yuki N, Hartung HP (2012) Guillain-Barr\u00e9 syndrome. N Engl J Med 366:2294\u20132304","journal-title":"N Engl J Med"},{"key":"2272_CR18","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.1016\/S0140-6736(05)67665-9","volume":"366","author":"RA Hughes","year":"2005","unstructured":"Hughes RA, Cornblath DR (2005) Guillain-Barr\u00e9 syndrome. Lancet 366:1653\u20131666","journal-title":"Lancet"},{"key":"2272_CR19","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1002\/ana.410440512","volume":"44","author":"RD Hadden","year":"1998","unstructured":"Hadden RD, Cornblath DR, Hughes RA, Zielasek J, Hartung HP, Toyka KV et al (1998) Electrophysiological classification of Guillain-Barr\u00e9 syndrome: clinical associations and outcome. Ann Neurol 44:780\u2013788","journal-title":"Ann Neurol"},{"key":"2272_CR20","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1016\/S1474-4422(08)70215-1","volume":"7","author":"PA Doorn van","year":"2008","unstructured":"van Doorn PA, Ruts L, Jacobs BC (2008) Clinical features, pathogenesis, and treatment of Guillain-Barr\u00e9 syndrome. Lancet Neurol 7:939\u2013950","journal-title":"Lancet Neurol"},{"key":"2272_CR21","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1001\/archneurol.2011.51","volume":"68","author":"KK Nyati","year":"2011","unstructured":"Nyati KK, Prasad KN, Rizwan A, Verma A, Paliwal VK (2011) TH1 and TH2 response to Campylobacter jejuni antigen in Guillain-Barre syndrome. Arch Neurol 68:445\u2013452","journal-title":"Arch Neurol"},{"issue":"Pt 6","key":"2272_CR22","first-page":"2053","volume":"119","author":"TIG-BS Group","year":"1996","unstructured":"Group TIG-BS (1996) The prognosis and main prognostic indicators of Guillain-Barr\u00e9 syndrome. A multicentre prospective study of 297 patients. Brain 119(Pt 6):2053\u20132061","journal-title":"Brain"},{"key":"2272_CR23","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/S0022-510X(02)00158-2","volume":"201","author":"RA Bernsen","year":"2002","unstructured":"Bernsen RA, de Jager AE, Schmitz PI, van der Mech\u00e9 FG (2002) Long-term impact on work and private life after Guillain-Barr\u00e9 syndrome. J Neurol Sci 201:13\u201317","journal-title":"J Neurol Sci"},{"key":"2272_CR24","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1007\/s00415-005-0958-x","volume":"253","author":"A Bersano","year":"2006","unstructured":"Bersano A, Carpo M, Allaria S, Franciotta D, Citterio A, Nobile-Orazio E et al (2006) Long term disability and social status change after Guillain-Barr\u00e9 syndrome. J Neurol 253:214\u2013218","journal-title":"J Neurol"},{"key":"2272_CR25","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1056\/NEJM199511233332102","volume":"333","author":"JH Rees","year":"1995","unstructured":"Rees JH, Soudain SE, Gregson NA, Hughes RA (1995) Campylobacter jejuni infection and Guillain-Barr\u00e9 syndrome. N Engl J Med 333:1374\u20131379","journal-title":"N Engl J Med"},{"key":"2272_CR26","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1212\/01.WNL.0000133205.05169.04","volume":"63","author":"S Kuwabara","year":"2004","unstructured":"Kuwabara S, Ogawara K, Misawa S, Koga M, Mori M, Hiraga A et al (2004) Does Campylobacter jejuni infection elicit \"demyelinating\" Guillain-Barr\u00e9 syndrome? Neurology 63:529\u2013533","journal-title":"Neurology"},{"key":"2272_CR27","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1111\/j.1085-9489.2005.0010209.x","volume":"10","author":"K Kamakura","year":"2005","unstructured":"Kamakura K, Kaida K, Kusunoki S, Miyamoto N, Masaki T, Nakamura R et al (2005) Harmful effects of anti-GalNAc-GD1a antibodies and TNF-alpha on rat dorsal root ganglia. J Peripher Nerv Syst 10:190\u2013201","journal-title":"J Peripher Nerv Syst"},{"key":"2272_CR28","doi-asserted-by":"crossref","first-page":"3540","DOI":"10.1002\/jnr.22514","volume":"88","author":"KK Nyati","year":"2010","unstructured":"Nyati KK, Prasad KN, Verma A, Paliwal VK (2010) Correlation of matrix metalloproteinases-2 and -9 with proinflammatory cytokines in Guillain-Barr\u00e9 syndrome. J Neurosci Res 88:3540\u20133546","journal-title":"J Neurosci Res"},{"key":"2272_CR29","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1177\/1352458511412996","volume":"17","author":"AJ Solomon","year":"2011","unstructured":"Solomon AJ, Spain RI, Kruer MC, Boudette D (2011) Inflammatory neurological disease in patients treated with tumor necrosis factor alpha inhibitors. Multiple Sclerosis J 17:1472\u20131487","journal-title":"Multiple Sclerosis J"},{"key":"2272_CR30","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1586\/14787210.1.4.597","volume":"1","author":"RS Tsang","year":"2003","unstructured":"Tsang RS, Valdivieso-Garcia A (2003) Pathogenesis of Guillain-Barre syndrome. Expert Rev Anti Infect Ther 1:597\u2013608","journal-title":"Expert Rev Anti Infect Ther"},{"key":"2272_CR31","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1007\/s00415-010-5591-7","volume":"257","author":"AG Tristano","year":"2010","unstructured":"Tristano AG (2010) Neurological adverse events associated with anti-tumor necrosis factor \u03b1 treatment. J Neurol 257:1421\u20131431","journal-title":"J Neurol"},{"key":"2272_CR32","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jneuroim.2011.03.004","volume":"234","author":"A Caminero","year":"2011","unstructured":"Caminero A, Comabella M, Montalban X (2011) Tumor necrosis factor alpha (TNF-\u03b1), anti-TNF-\u03b1 and demyelination revisited: an ongoing story. J Neuroimmunol 234:1\u20136","journal-title":"J Neuroimmunol"},{"key":"2272_CR33","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1136\/ard.2009.111500","volume":"69","author":"S Bernatsky","year":"2010","unstructured":"Bernatsky S, Renoux C, Suissa S (2010) Demyelinating events in rheumatoid arthritis after drug exposures. Ann Rheum Dis 69:1691\u20131693","journal-title":"Ann Rheum Dis"},{"key":"2272_CR34","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1038\/clpt.1981.154","volume":"30","author":"CA Naranjo","year":"1981","unstructured":"Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA et al (1981) A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 30:239\u2013245","journal-title":"Clin Pharmacol Ther"},{"key":"2272_CR35","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1002\/1529-0131(200002)43:2<243::AID-ANR2>3.0.CO;2-K","volume":"43","author":"FW Miller","year":"2000","unstructured":"Miller FW, Hess EV, Clauw DJ, Hertzman PA, Pincus T, Silver RM et al (2000) Approaches for identifying and defining environmentally associated rheumatic disorders. Arthritis Rheum 43:243\u2013249","journal-title":"Arthritis Rheum"},{"issue":"5","key":"2272_CR36","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1093\/rheumatology\/kes375","volume":"52","author":"R Seror","year":"2013","unstructured":"Seror R, Richez C, Sordet C, Rist S, Gossec L, Direz G et al (2013) Pattern of demyelination occurring during anti-TNF-\u03b1 therapy: a French national survey. Rheumatology 52(5):868\u201374","journal-title":"Rheumatology"},{"key":"2272_CR37","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1016\/S1474-4422(06)70552-X","volume":"5","author":"LF Barcellos","year":"2006","unstructured":"Barcellos LF, Kamdar BB, Ramsay PP, DeLoa C, Lincoln RR, Caillier S et al (2006) Clustering of autoimmune diseases in families with a high-risk for multiple sclerosis: a descriptive study. Lancet Neurol 5:924\u2013931","journal-title":"Lancet Neurol"},{"key":"2272_CR38","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1111\/j.1600-0404.1996.tb00004.x","volume":"93","author":"R Midgard","year":"1996","unstructured":"Midgard R, Gr\u00f8nning M, Riise T, Kv\u00e5le G, Nyland H (1996) Multiple sclerosis and chronic inflammatory diseases. A case\u2013control study. Acta Neurol Scand 93:322\u2013328","journal-title":"Acta Neurol Scand"},{"key":"2272_CR39","doi-asserted-by":"crossref","first-page":"2217","DOI":"10.1093\/rheumatology\/keq249a","volume":"49","author":"T Ding","year":"2010","unstructured":"Ding T, Ledingham J, Luqmani R, Westlake S, Hyrich K, Lunt M et al (2010) BSR and BHPR rheumatoid arthritis guidelines on safety of anti-TNF therapies. Rheumatology (Oxford) 49:2217\u20132219","journal-title":"Rheumatology (Oxford)"},{"key":"2272_CR40","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1007\/s10067-012-2113-2","volume":"32","author":"T Matsumoto","year":"2013","unstructured":"Matsumoto T, Nakamura I, Miura A, Momoyama G, Ito K (2013) New-onset multiple sclerosis associated with adalimumab treatment in rheumatoid arthritis: a case report and literature review. Clin Rheumatol 32:271\u2013275","journal-title":"Clin Rheumatol"},{"key":"2272_CR41","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1001\/archneurol.2009.11","volume":"66","author":"P Lozeron","year":"2009","unstructured":"Lozeron P, Denier C, Lacroix C, Adams D (2009) Long-term course of demyelinating neuropathies occurring during tumor necrosis factor-alpha-blocker therapy. Arch Neurol 66:490\u2013497","journal-title":"Arch Neurol"},{"key":"2272_CR42","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1001\/archneurol.2011.154","volume":"68","author":"SH Kim","year":"2011","unstructured":"Kim SH, Kim W, Li XF, Jung IJ, Kim HJ (2011) Repeated treatment with rituximab based on the assessment of peripheral circulating memory B cells in patients with relapsing neuromyelitis optica over 2 years. Arch Neurol 68:1412\u20131420","journal-title":"Arch Neurol"},{"key":"2272_CR43","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1038\/bmt.2008.81","volume":"42","author":"F Ostronoff","year":"2008","unstructured":"Ostronoff F, Perales MA, Stubblefield MD, Hsu KC (2008) Rituximab-responsive Guillain-Barr\u00e9 syndrome following allogeneic hematopoietic SCT. Bone Marrow Transplant 42:71\u201372","journal-title":"Bone Marrow Transplant"},{"issue":"Suppl 1","key":"2272_CR44","doi-asserted-by":"crossref","first-page":"S19","DOI":"10.1097\/01.wco.0000313360.38306.ab","volume":"21","author":"K Hawker","year":"2008","unstructured":"Hawker K (2008) B-cell-targeted treatment for multiple sclerosis: mechanism of action and clinical data. Curr Opin Neurol 21(Suppl 1):S19\u2013S25","journal-title":"Curr Opin Neurol"},{"key":"2272_CR45","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1007\/s00415-009-5400-3","volume":"257","author":"R Jaso","year":"2010","unstructured":"Jaso R, Sierra M, Calleja J, Valero C, Pascual J (2010) Guillain-Barr\u00e9 syndrome after rituximab in a patient with idiopathic thombocytopenic purpura: a causal association? J Neurol 257:488\u2013489","journal-title":"J Neurol"},{"key":"2272_CR46","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1111\/j.1529-8027.2007.00134.x","volume":"12","author":"F Terenghi","year":"2007","unstructured":"Terenghi F, Ardolino G, Nobile-Orazio E (2007) Guillain-Barr\u00e9 syndrome after combined CHOP and rituximab therapy in non-Hodgkin lymphoma. J Peripher Nerv Syst 12:142\u2013143","journal-title":"J Peripher Nerv Syst"},{"key":"2272_CR47","doi-asserted-by":"crossref","first-page":"1792","DOI":"10.1002\/art.27431","volume":"62","author":"N Ruperto","year":"2010","unstructured":"Ruperto N, Lovell DJ, Quartier P, Paz E, Rubio-P\u00e9rez N, Silva CA et al (2010) Long-term safety and efficacy of abatacept in children with juvenile idiopathic arthritis. Arthritis Rheum 62:1792\u20131802","journal-title":"Arthritis Rheum"}],"container-title":["Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-013-2272-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10067-013-2272-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-013-2272-9","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,29]],"date-time":"2019-05-29T08:57:26Z","timestamp":1559120246000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10067-013-2272-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,5,11]]},"references-count":47,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2013,9]]}},"alternative-id":["2272"],"URL":"https:\/\/doi.org\/10.1007\/s10067-013-2272-9","relation":{},"ISSN":["0770-3198","1434-9949"],"issn-type":[{"value":"0770-3198","type":"print"},{"value":"1434-9949","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,5,11]]}}}